Crispr Therapeutics AG (CRSP)
3 Things You Need to Know if You Buy CRISPR Therapeutics Today
CRISPR Therapeutics (CRSP -3.57%) is recognized as a pioneer in the field of gene therapy. This biotechnology has the potential to revolutionize medicine through precise modifications of a person's DNA to treat and cure genetic diseases.
CRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock?
CRISPR Therapeutics (CRSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 Biotech Stocks to Buy Hand Over Fist in December
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500.
Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Could Surge 58.3%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 58.3% in CRISPR Therapeutics (CRSP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%
Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding on for the long term. The idea is to get in on these players for a bargain price, and then benefit as they launch products and revenue gains momentum.
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
On Nov. 21, shares of CRISPR Therapeutics (CRSP 3.44%) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies.
CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Jefferies London Healthcare Conference November 20, 2024 11:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conference Call Participants Maury Raycroft - Jefferies Maury Raycroft Hi, everyone. My name is Maury Raycroft, I'm one of the biotech analysts at Jeffreys.
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?
The decline in CRSP's share price could be due to the beating the drug/biotech sector has been taking in the past couple of months, resulting from pipeline setbacks and guidance cuts.
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Samarth Kulkarni - CEO and Chairman Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good afternoon and thank you for joining us at Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit and one of the therapeutic analysts here.
